GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Selling, General, & Admin. Expense

HLS Therapeutics (TSX:HLS) Selling, General, & Admin. Expense : C$35.63 Mil (TTM As of Mar. 2025)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. HLS Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2025 was C$8.07 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2025 was C$35.63 Mil.


HLS Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for HLS Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Selling, General, & Admin. Expense Chart

HLS Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.20 33.76 40.56 37.95 38.36

HLS Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.45 9.55 9.21 8.81 8.07

Competitive Comparison of HLS Therapeutics's Selling, General, & Admin. Expense

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Selling, General, & Admin. Expense falls into.


;
;

HLS Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$35.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (TSX:HLS) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


HLS Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.
Executives
Norma Beauchamp Director
Jr. John Lee Welborn Director
Craig Millian Director, Senior Officer
Brian Thomas Walsh Senior Officer
Polar Asset Management Partners Inc. 10% Security Holder
John Gordon Hanna Director, Senior Officer
Athyrium Opportunities Ii Co-invest 1 Lp 10% Security Holder
Tim Hendrickson Senior Officer
William M. Wells Director, Senior Officer
Gilbert Godin Director, Senior Officer
Gregory David Gubitz Director
Orbimed Advisors Llc 10% Security Holder
Jason Gross Senior Officer
Ryan Christopher Lennox Senior Officer

HLS Therapeutics Headlines

No Headlines